Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis
{{output}}
Background: The therapeutic landscape for ulcerative colitis (UC) has recently broadened to include anti-TNFα, anti-integrin, and anti-IL-12/23p40 antibody agents. These biological agents are tailored to individual patient profi... ...
